Dengue Epidemiology and Burden of Disease in Latin America and the Caribbean: A Systematic Review of the Literature and Meta-Analysis

Cafferata, María Luisa; Bardach, Ariel; Rey‐Ares, Lucila; Alcaráz, Andrea; Cormick, Gabriela; Gibbons, Luz; Romano, Marina; Cesaroni, Silvana; Ruvinsky, Silvina

doi:10.1016/j.vhri.2013.10.002

Cited by 58 publications

(71 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, each model assumed that a fixed proportion of hospitalised cases will die. The probability of death was assumed to be in the range of 0.03% to 0.09% for symptomatic dengue cases (S1 Appendix Table B), based on a review of surveillance data and published studies from Latin American countries [1,35–38]. …”

Section: Methodsmentioning

confidence: 99%

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

et al. 2016

View full text Add to dashboard Cite

BackgroundLarge Phase III trials across Asia and Latin America have recently demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 mo following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. We here report predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine vaccination with Dengvaxia in a range of transmission settings, as characterised by seroprevalence levels among 9-y-olds (SP9). These predictions were conducted for the World Health Organization to inform their recommendations on optimal use of this vaccine.Methods and FindingsThe models adopted, with small variations, a parsimonious vaccine mode of action that was able to reproduce quantitative features of the observed trial data. The adopted mode of action assumed that vaccination, similarly to natural infection, induces transient, heterologous protection and, further, establishes a long-lasting immunogenic memory, which determines disease severity of subsequent infections. The default vaccination policy considered was routine vaccination of 9-y-old children in a three-dose schedule at 80% coverage. The outcomes examined were the impact of vaccination on infections, symptomatic dengue, hospitalised dengue, deaths, and cost-effectiveness over a 30-y postvaccination period. Case definitions were chosen in accordance with the Phase III trials.All models predicted that in settings with moderate to high dengue endemicity (SP9 ≥ 50%), the default vaccination policy would reduce the burden of dengue disease for the population by 6%–25% (all simulations: –3%–34%) and in high-transmission settings (SP9 ≥ 70%) by 13%–25% (all simulations: 10%– 34%). These endemicity levels are representative of the participating sites in both Phase III trials. In contrast, in settings with low transmission intensity (SP9 ≤ 30%), the models predicted that vaccination could lead to a substantial increase in hospitalisation because of dengue. Modelling reduced vaccine coverage or the addition of catch-up campaigns showed that the impact of vaccination scaled approximately linearly with the number of people vaccinated. In assessing the optimal age of vaccination, we found that targeting older children could increase the net benefit of vaccination in settings with moderate transmission intensity (SP9 = 50%). Overall, vaccination was predicted to be potentially cost-effective in most endemic settings if priced competitively.The results are based on the assumption that the vaccine acts similarly to natural infection. This assumption is consistent with the available trial results but cannot be directly validated in the absence of additional data. Furthermore, uncertainties remain regarding the level of protection provided against disease versus infection and the rate at whi...

show abstract

Section: Methodsmentioning

confidence: 99%

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…About 40% of the world's population live in countries where the risk of transmission is high. The world health organization (WHO) estimates that every year about 500,000 cases with DHF (22,000 deaths) occur (6,7). Treatment is supportive and patients should rest and use acetaminophen.…”

Section: Contextmentioning

confidence: 99%

“…Dengue fever (DF) occurs when one of the four serotypes of virus infects human (1,2,6,9). Infection with one serotype cannot protect human against the other serotypes.…”

Section: Epidemiologymentioning

confidence: 99%

“…Climate changes can have a significant effect on the incidence and prevalence rate of infection. In many of tropical and subtropical countries, dengue is endemic and disease occurs every year, when rainfall is optimal for breeding (1,4,6,(14)(15)(16). Dengue epidemic happens when a large numbers of mosquitoes feed on the large numbers of people who have no immunity to one of the serotypes.…”

Section: Epidemiologymentioning

confidence: 99%

“…Today, about 2.5 billion people (near 40% of the world's population) live in countries where the risk of transmission is high. World health organization estimates that about 50-100 million of world populations become infected yearly, and among them 500,000 DHF with 22,000 deaths (more among young children) are reported (1,6,14,19). Travellers who returning to Europe countries usually get DF from South-east Asia, particularly Thailand and Philippines; however, in the USA dengue found in travelers returning from Mexico and Dominican Republic (20).…”

Section: Epidemiologymentioning

confidence: 99%

See 2 more Smart Citations

Dengue: A Re-Emerging Disease

Sharifi-Mood

Mardani

2016

Arch Clin Infect Dis

View full text Add to dashboard Cite

Context: Dengue fever (DF) is caused by an arbovirus, which transmitted to humans through the bite of an infected mosquito (Aedes species). Near 2.5 billion people are living in regions where the risk of transmission is high. Until the mid of 20 th century, DF was restricted to special parts of tropical and subtropical regions. Dengue hemorrhagic fever (DHF) was first reported in the 1950s when two epidemics happened in the Philippines and Thailand. Now, with international travels and climate changes, its geographical distribution has been changed and increased. Evidence Acquisition: We searched medical databases (PubMed and Scopus) from March 1960 to Feb 2015. The key words for the review of literature were as follows: dengue, dengue fever, dengue hemorrhagic fever, epidemiology, transmission routes, clinical manifestation, treatment and prevention of dengue.Results: Upon the results from literature search, the researchers found that human is the main reservoir for this virus. There are four serotypes of virus. Infection with one serotype cannot protect human against the other three serotypes. Dengue fever begins suddenly with an onset of an influenza-like syndrome and sometimes progresses to severe form of the disease. Treatment is supportive and includes diminishing the fever and balancing fluids and electrolytes. Real-time polymerase chain reaction assays, IgM and IgG-ELISA, and the NS1 ELISA-based antigen assay are available for diagnosis of DHF. There is no FDA-approved vaccine. Mosquito control is the main way for the prevention of dengue. Conclusions: Dengue virus is not highly contagious and virus cannot be spread directly from person to person. Understanding the epidemiology, clinical manifestation, prompt diagnosis, suitable prevention routes such as mosquito control, and also coordinated effort in the community for disease control are important issues.

show abstract

Oxime derivatives with larvicidal activity against Aedes aegypti L.

et al. 2015

View full text Add to dashboard Cite

Oximes containing secondary metabolites constitute an important group of bioactive compounds and have been described and frequently updated in the literature due to their pharmacological properties. Thus, the aim of this study was to evaluate the larvicidal activity of a series of fourteen structurally related [1,4]-Benzoquinone mono-oximes on third-instar Aedes aegypti larvae and to investigate structure-activity relationships (SAR) of these compounds. Results of larvicidal assay revealed that all oximes were found to have larvicidal activity. Compound 2,6-dimethyl-[1,4]-benzoquinone oxime tosylate (11) was the most bioactive (LC50 = 9.858 ppm), followed by 2-methyl-[1,4]-benzoquinone oxime tosylate (9) (LC50 = 14.450 ppm). [1,4]-benzoquinone oxime (1) exhibited the lowest potency, with an LC50 = 121.181 ppm. The molecular characteristics which may help to understand the assayed compounds larvicidal activity were identified. SAR indicates that the addition of alkyl groups attached to the ring, number, position in the unsaturated cyclic structure, and size of these groups influence the larvicidal activity. Moreover, the lipophilicity seems to play an important role in increasing the larvicidal effect, because, in general, tosyl-containing products were more potent than products containing free OH.

show abstract

Dengue Epidemiology and Burden of Disease in Latin America and the Caribbean: A Systematic Review of the Literature and Meta-Analysis

Abstract: Activities to control dengue transmission in the region have been important but insufficient. The surveillance of dengue burden of disease and circulating strains help shape and evaluate the present and future health policies.

Cited by 58 publications

References 41 publications

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

Dengue: A Re-Emerging Disease

Oxime derivatives with larvicidal activity against Aedes aegypti L.

Contact Info

Product

Resources

About